Australian company Neuren Pharmaceuticals (ASX:NEU) has received the upfront payment of US$100 million that was earned following the recent global expansion of its partnership with Acadia Pharmaceuticals for DAYBUE (trofinetide). …
Neuren receives US$100 million initial payment for expanded DAYBUE agreement
July 27, 2023 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News -
Johnson & Johnson the latest to sign 'Most Favored Nation' agreement with Trump administration
January 11, 2026 - - Latest News -
Reading between the reform lines - what the 2005 Cabinet papers can teach us today
January 11, 2026 - - Latest News -
New treatment listed on PBS, offering twice-yearly dosing for Australians with relapsing MS
January 9, 2026 - - Latest News -
The value of looking back and the importance of seeing the 'smoke signals' on reform
January 8, 2026 - - Latest News -
Vaxxas appoints former global vaccines leader to head global commercialisation push
January 8, 2026 - - Australian Biotech